Effect of iron-chelating agents on inhibitors of ribonucleotide reductase.
D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000201:enzymology; D002614:Chelating Agents / Q000494:pharmacology*; D003676:Deferoxamine / Q000494:pharmacology; D004492:Edetic Acid / Q000494:pharmacology; D005260:Female; D006144:Guanazole / Q000494:pharmacology; D006918:Hydroxyurea / Q000494:pharmacology; D007502:Iron Chelating Agents; D051379:Mice; D008813:Mice, Inbred ICR; D015125:Oxyquinoline / Q000494:pharmacology; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors*
D002614:Chelating Agents; D007502:Iron Chelating Agents; D015125:Oxyquinoline; D004492:Edetic Acid; D012264:Ribonucleotide Reductases; D006144:Guanazole; D003676:Deferoxamine; D006918:Hydroxyurea